Stuart Poulton, EVP, Chief Development Officer at Karyopharm Therapeutics Inc. (KPTI), sold 3,548 shares at $6.29 ($22K) on 2025-03-04, disclosed to the SEC on 2025-03-06.
Open-market sale of $22k KPTI by EVP, Chief Development Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| KPTI | SELL | 2026-03-03 | $48K | — | Filing → |
| KPTI | SELL | 2026-02-19 | $3K | — | Filing → |
| KPTI | SELL | 2025-09-16 | $3K | — | Filing → |